Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

WW International relists on Nasdaq, pivoting to menopause care with GLP-1 drugs and coaching. Click here to read an analysis ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

On this news, Hims & Hers' stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Investing.com -- Hims & Hers CEO Andrew Dudum has shared new information about the company’s terminated partnership with Novo Nordisk (NYSE: NVO ), which ended in June 2025, in an interview with The ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.

In this episode of The NBR Podcast with Simon Shepherd: Obesity. Conservatively, it's a two-billion-dollar problem. But the ...

The research, published in the Canadian Medical Association Journal (CMAJ) Monday, found that 32.7 per cent of Canadians ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging.

An Ozempic user has revealed what they believe is a 'terrifying' side effect of upping their Ozempic dose. Falling into the category of GLP-1 medications, Ozempic is FDA-approved for type two diabetes ...